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Background. The occurrence of clarithromycin resistance 
among Helicobacter pylori strains is a major cause of the 
treatment failure. Resistance to this drug is conferred 
by point mutations in 23S rRNA gene and the most 
prevalent mutations are A2143G and A2142G. The aim 
of the study was to evaluate the occurrence of A2143G 
and A2142G mutations in a group of H.  pylori strains 
resistant to clarithromycin. Materials and Methods. 
The study included 21 clarithromycin-resistant H.  pylo-
ri strains collected between 2006 and 2009 in southern 
Poland. Resistance to clarithromycin was quantitatively 
tested with the E-test to determine the minimal inhib-
itory concentration (MIC value). The point mutations 
of H.  pylori isolates were detected by PCR followed by 
RFLP analysis. Results. The MIC values for clarithromy-
cin for the analyzed strains ranged from 1.5  mg/L to 
64  mg/L. Nine H.  pylori strains exhibited A2143G mu-
tation and A2142G mutation was found in 9 isolates as 
well. The results of RFLP analysis of 3 clarithromycin-re-
sistant strains were negative for both mutations. The av-
erage MIC values for A2143G and A2142G mutants were 
6 and 30  mg/L, respectively. Conclusions. Frequencies 
of A2143G and A2142G mutations were the same in all 
isolates tested. Strains with A2143G mutation exhibited 
lower MIC values than A2142G mutants. Application of 
PCR-RFLP method for detection of clarithromycin resis-
tance allows for better and more efficient management 
of H. pylori infections.
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INTRODUCTION
Helicobacter pylori is a Gram-negative, spiral-shaped, mi-
croaerophilic bacterium which colonizes gastric mucosa 
of 50% of the human population worldwide. Moreover, 
H. pylori is a major cause of upper gastrointestinal tract 
diseases such as: dyspepsia, type B gastritis, gastric ul-
cer disease, and duodenal ulcer disease (Perez-Perez et 
al., 2004; Malfertheiner et al., 2012; den Hollander, 2013). 
H. pylori is also considered as a class I carcinogen, in-
volved in the formation of gastric cancer and muco-
sa-associated lymphoid tissue (MALT) lymphoma (IARC, 
1994; Ando et al., 2006; Konturek et al., 2009; Gisbert et 
al., 2011; Figueiredo et al., 2013).
Current recommendations for the management of 
H. pylori infection were elaborated by the European He-
licobacter Study Group (EHSG) and presented in Maas-
tricht IV/Florence Consensus Report in 2012. According 
to these guidelines, an effective treatment requires com-
bined therapy, and it is important to take into consider-
ation H. pylori resistance to clarithromycin on the area 
the patient is coming from (areas of low (<20%) and 
high (>20%) prevalence) (Malfertheiner et al., 2012).
Clarithromycin is one of the most common compo-
nents of H. pylori infection treatment schemes. It is in-
cluded in the standard triple therapies, as well as in 
non-bismuth quadruple therapies (either sequential or 
concomitant) (Malfertheiner et al., 2012). Moreover, clar-
ithromycin is found to be one of the most effective an-
timicrobial agents used in the treatment of H. pylori in-
fection (de Francesco et al., 2006). However, it should 
be remembered, that the development of clarithromycin 
resistance is a major cause of H. pylori treatment failure 
(Mégraud, 2004; Giorgio et al., 2013).
Clarithromycin is a semisynthetic 14-membered mac-
rolide antibiotic with bacteriostatic activity against 
broad-spectrum of microorganisms including H. pylori. 
Due to this fact, this drug is widely used in the treat-
ment of respiratory tract and skin diseases, as well as 
upper-gastrointestinal tract diseases caused by H. pylori. 
While clarithromycin is relatively stable in gastric juice, 
the use of an acid-suppressive drug (e.g. proton pumps 
inhibitor (PPI)) enhances the therapeutic effect of this 
antimicrobial agent. Moreover, therapeutic activity of 
clarithromycin is also related to its delivery to the gastric 
mucosa (Erah et al., 1997; Dzierżanowska, 2009; Fuki et 
al., 2011).
Antibacterial activity of clarithromycin is related to 
inhibition of bacterial protein synthesis by reversible 
binding to the 50S ribosomal subunits. The target site of 
clarithromycin is the peptidyl transferase loop of V do-
main of 23S ribosomal RNA molecule. Because of this 
binding, the translocation of aminoacyl transfer-RNA is 
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effectively blocked resulting in the inhibition of protein 
synthesis (Dzierżanowska, 2009; Gerrits et al., 2006).
Resistance to clarithromycin is associated with the 
target site modifications and efflux pumps. Target site 
modifications are mediated by two mechanisms: 1) point 
mutations in the peptidyl transferase-encoding region of 
V domain of 23S rRNA gene and 2) post-transcription-
al methylation of 23S rRNA region (Gerrits et al., 2006; 
Mégraud & Lehours, 2007; Hirata et al., 2010).
The mechanism of clarithromycin resistance in H. py-
lori is mainly associated with the following point muta-
tions in 23S rRNA gene:
1) A2143G (previously described as A2144G) occurring 
in 69.8% of strains;
2) A2142G (previously described as A2143G) occurring 
in 11.7% of isolates;
3) A2142C reported in 2.6% strains (Taylor et al., 1997; 
Mégraud, 2004; Gerrits et al., 2006; Karczewska et al., 
2009; Francavilla et al., 2010).
Moreover, other mutations such as A2115G, G2141A, 
C2147G, T2190C, C2195T, A2223G, and C2694A 
have been identified among H. pylori strains resistant to 
clarithromycin, although their role in the mechanism of 
resistance remains unclear (Hao et al., 2004; Mégraud, 
2004; Gerrits et al., 2006; Agudo et al., 2010).
One of the major factors contributing to clarithromy-
cin resistance of H. pylori strains is high outpatient con-
sumption of clarithromycin, especially in the treatment of 
respiratory tract diseases (Mégraud, 2004; Mégraud et al., 
2013). Mean rate of H. pylori clarithromycin resistance in 
Europe amounted to 17.5%. However, diversity between 
the regions could be observed: 7.7% in the Northern 
European countries, 18.7% in Western/Central Europe, 
and 21.5% in Southern Europe (Mégraud et al., 2013). 
In Poland, according to our recent studies conducted in 
the years 2006–2008 and 2009–2011, the rate of H. pylo-
ri clarithromycin resistance among adults was 34% and 
22%, respectively (Karczewska et al., 2011; Karczewska 
et al., 2012). Therefore, according to the Maastricht IV/
Florence Consensus Report, southern Poland should be 
classified as a high clarithromycin resistance region (Mal-
fertheiner et al., 2012).
Over the years, numerous methods have been devel-
oped to detect the resistance of H. pylori to clarithro-
mycin. These methods can be divided into two groups: 
phenotypic and genotypic. Antibiotic susceptibility test-
ing of H. pylori is routinely performed with the use of 
phenotypic methods. This assay, preceded by culturing 
of bacteria, includes both agar dilution technique and 
the use of strips impregnated with antimicrobial agent 
gradient (e.g. E-test, bioMérieux, France). In addition, 
these methods are labor-intensive and time-consuming; 
full testing takes up to two weeks. Unfortunately, as es-
timated, culture based methods fail in about 10% of cas-
es due to contamination of biopsy specimens or growth 
difficulties (Gerrits et al., 2006). While culture-based phe-
notypic methods are time consuming, nucleic acid-based 
techniques could offer a faster and more accurate alter-
native. Molecular detection of clarithromycin resistance 
among H. pylori strains is mostly based on analysis of the 
unique point mutations in 23S rRNA gene. These tech-
niques make it possible to determine the resistance pro-
files of H. pylori strains from cultured isolates as well as 
directly from biopsies or stool samples (Oleastro et al., 
2003; Booka et al., 2005; Rimbara et al., 2005; Ho et al., 
2010). The most important methods used to detect mu-
tations are PCR followed by RFLP (restriction fragment 
length polymorphism) and Real-Time PCR (using SYBR-
Green and/or labeled probes), although other methods 
are applied as well: PCR-DNA enzyme immunoassay, 
mismatched PCR, hybridization and sequencing tech-
niques (Chisholm et al., 2001; Mégraud, 2004; Schabere-
iter-Gurtner et al., 2004; Gerrits et al., 2006; Agudo et al., 
2010). While molecular methods are more reliable and 
less time-consuming than the phenotypic ones, they are 
still not routinely used for detection of clarithromycin-re-
sistant H. pylori strains in Poland. PCR-RFLP is per-
formed to detect the most common point mutations in 
23S rRNA gene, such as: A2143G, A2142G and A2142C 
(Occhialini et al., 1997; Ménard et al., 2002; Agudo et al., 
2011). This method is based on the presence or absence 
of the sites recognized by restriction enzymes within the 
amplified DNA fragment (Gerrits et al., 2006; Mégraud 
& Lehours, 2007).
The aim of the present study was to detect the two 
most prevalent point mutations: A2143G and A2142G 
in 23S rRNA gene associated with clarithromycin resist-
ance of H. pylori strains with the use of PCR-RFLP tech-
nique.
MATERIALS AND METHODS
Gastric biopsy specimens and H.  pylori strains. 
Twenty-one clarithromycin-resistant H. pylori clinical 
strains subjected to the study were obtained from gastric 
biopsy specimens of patients with upper-gastrointestinal 
tract diseases, from Falck Medycyna Outpatient Clinic of 
Gastroenterology (Krakow, Poland) between 2006 and 
2009.
H. pylori strains were isolated according to the follow-
ing procedure:
 – homogeneous tissue was spread onto both: non selec-
tive (Schaedler agar with 5% sheep blood, bioMérieux, 
France) and selective (Schaedler agar with 5% sheep 
blood and selective supplement Dent, Oxoid, UK) me-
dia and incubated up to 10 days under microaerophilic 
conditions at 37°C;
 – identification of H. pylori strains was based on: micro-
scopic appearance of colonies, negative Gram staining 
and positive biochemical tests for urease, catalase and 
oxidase;
 – isolated strains were frozen and stored at –80°C for 
further analysis in Scheadler anaerobe broth (Oxoid, 
UK) supplemented with fetal bovine serum (Sigma-Al-
drich, Germany) and glycerol (POCH, Poland).
The design of the study was approved by the Bioethi-
cal Commission of the Jagiellonian University and each 
patient signed an informed consent before participation 
in the study.
Determination of the clarithromycin resist-
ance with the use of phenotypic method (E-test). 
Clarithromycin resistance was determined quantitatively, 
as the minimal inhibitory concentration (MIC value), 
with the use of strips impregnated with the antibiotic 
gradient (E-test, bioMérieux, France). Colonies were 
taken from the pure H. pylori cultures and suspended in 
sterile saline (NaCl 0.85% Medium, bioMérieux, France) 
on an equivalent of 3.0 McFarland units. The inoculum 
was spread onto Schaedler agar medium with 5% sheep 
blood (bioMérieux, France) with sterile cotton swabs. E-
test strips with clarithromycin gradient were separately 
placed on inoculated plates according to the manufac-
turer recommendations (E-test technical manual, bio-
Mérieux, France). The inoculated plates with strips were 
incubated under microaerophilic conditions for 72 hours 
at 37°C.
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H. pylori strains were classified as resistant when the 
clarithromycin MIC values exceeded 0.5 mg/L (accord-
ing to the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) breakpoint tables for inter-
pretation of MICs and zone diameters).
Bacterial genomic DNA extraction. DNA was 
extracted from pure 72-hour H. pylori cultures. Colo-
nies were suspended in 1 ml of sterile saline (NaCl 
0.85% Medium, bioMérieux, France) and centrifuged 
(12000 rpm/3 min). Total bacterial genomic DNA was 
isolated with the use of Sherlock AX isolation kit (A&A 
Biotechnology, Poland), according to the manufacturer’s 
recommendations. The eluted DNA was stored at –20°C 
until use.
Determination of the clarithromycin resistance 
with the use of genotypic method (PCR-RFLP). De-
tection of the most common point mutations (A2143G, 
A2142G) conferring resistance to clarithromycin in 
H. pylori strains was performed by PCR followed by 
RFLP analysis.
PCR assay was conducted using primers and thermal 
profiles described by Agudo (Agudo et al., 2011) (K1 – 
sense: CCA CAG CGA TGT GGT CTC AG and K2 
– antisense: CTC CAT AAG AGC CAA AGC CC). The 
reaction mixture of the final volume 25 µl contained: 
2 µl of genomic DNA, 2 µl of each primer, 5 µl of Go-
Taq® Flexi Buffer, 1.5 µl of MgCl2 (25 mM), 0.5 µl of 
PCR Nucleotide Mix (10 mM each), 0.125 µl of GoTaq® 
DNA Polymerase (5 u/μl) and Nuclease-Free Water 
(Promega, USA).
Amplicon of 425-base-pairs was visualized after elec-
trophoresis in 2% agarose gel stained with ethidium bro-
mide.
The RFLP assay was carried out with Eco31I (BsaI) 
enzyme (Thermo Scientific, USA) in order to detect 
A2143G mutation, while BbsI enzyme (New England 
Biolabs, USA) was used to detect A2142G mutation. 
Digestion thermal profiles are shown in Table 1. The 
analysis was carried out against ATCC 700684 refer-
ence clarithromycin-resistant H. pylori strain possessing 
A2143G mutation.
RESULTS AND DISCUSSION
H. pylori resistance to clarithromycin is predominantly 
related to the point mutations in the peptidyl transferase-
encoding region of V domain of 23S rRNA gene. The 
most prevalent point mutations responsible for this 
process are A2143G, A2142G, and A2142C (Mégraud, 
2004).
Prevalence of point mutations
PCR-RFLP analysis was performed on 21 H. pylori 
strains resistant to clarithromycin in order to detect 
the two most common point mutations: A2143G and 
A2142G in 23S rRNA gene. Figure 1 shows the results 
of restriction fragment length polymorphism analysis of 
23S rRNA amplicons (425 bp) with Eco31I (BsaI) and 
BbsI enzymes.
Among 21 clarithromycin-resistant H. pylori strains in-
cluded in our study, more than 90% of isolates carried 
A2143G (9; 42.9%) or A2142G (9; 42.9%) mutation. 
Therefore, our research confirms the reports of several 
authors that the predominant mutations responsible for 
clarithromycin resistance in H. pylori are A2143G and 
A2142G (Occhialini et al., 1997; Mégraud, 2004).
Prevalence of the particular point mutations varies 
across geographical areas. Versalovic et al. (1997) showed 
that the majority of H. pylori isolates from American pa-
tients carried A2143G (previously A2144G) mutation 
(52.5%), whereas 39% of strains contained A2142G (pre-
viously A2143G) mutation. Also, among French patients, 
A2143G mutation was predominant in clarithromycin-
resistant strains — 90% of A2143G vs. 10% of A2142G 
mutants (Raymond et al., 2007). Alvarez et al. (2009) con-
firmed that A2143G mutation was more frequent among 
patients from Colombia and could be found in 75% of 
H. pylori clarithromycin-resistant strains. According to 
the review conducted by Mégraud (Mégraud, 2004), the 
most common mutation was A2143G that occurred in 
about 69.8% of strains resistant to clarithromycin, but its 
prevalence varied from 52.7% in Germany up to 95.6% 
in Hong Kong. In Poland, 72% of the clarithromycin-
resistant strains isolated from children, were reported to 
carry A2143G mutation (Rożynek et al., 2002). The aver-
age prevalence of A2142G mutation amounted to 11.7% 
and ranged from 5% of the resistant strains in Iran 
to 66.6% in Japan (Mégraud, 2004). Twenty per cent 
of H. pylori strains isolated from Polish patients were 
A2142G mutants (Rożynek et al., 2002). While most re-
searchers concluded that A2143G mutation was more 
common than A2142G one (Versalovic et al., 1997; Mé-
Table 1. Conditions of digestion with restriction enzymes (enzymes, thermal profiles and products size).
Mutation Enzyme Thermal profile Products size References
A2143G Eco31I (BsaI) 37°C (30 min), 65°C (5 min) 304 bp and 101 bp Agudo et al., 2011
A2142G BbsI 37°C (24 h) 332 bp and 93 bp Occhialini et al., 1997
Figure 1. RFLP analysis of 23S rRNA amplicons (425 bp) digest-
ed with:
(Part A) Eco31I (BsaI) enzyme (digestion products of 304 and 101 
bp — for A2143G mutants); (Part B) BbsI enzyme (digestion prod-
ucts of 332 and 93 bp — for A2142G mutants); Lines 1–10: clini-
cal H.  pylori isolates; Lines 1, 3, 5, 7, 10: A2142G H.  pylori mutants; 
Lines 2, 4, 6, 8: A2143G H.  pylori mutants; Line 9: clarithromycin-
resistant isolate with negative results for both assayed mutations; 
P — H.  pylori ATCC 700684; M — Molecular Weight Marker (50 bp 
O’Gene Ruler, Thermo Scientific, USA).
314           2014K. Klesiewicz and others
graud, 2004; Raymond et al., 2007; Agudo et al., 2011), 
we observed equal prevalence of both mutations in all 
analyzed strains. The discrepancies between our results 
and the results of other authors may have arisen from 
either geographical origin of the isolates or limited num-
ber of tested strains.
Our PCR-RFLP analysis revealed also the occurrence 
of three clarithromycin-resistant strains (14.2%) without 
any of the assayed mutations. In these isolates, resist-
ance to clarithromycin might be associated with other 
less common mutations or with the efflux mechanism. 
Therefore, further analysis are required. In future, these 
mechanisms could be detected using PCR-RFLP or Re-
al-Time PCR (Menard et al., 2002; Mégraud & Lehours, 
2007).
Association between the type of mutation and the 
level of clarithromycin resistance
According to some authors, different types of muta-
tions are associated with different MIC values (Raymond 
et al., 2007). Correlation between the type of mutation 
and the MIC value for 21 analyzed H. pylori isolates is 
presented in Table 2. In our study, a MIC value ex-
ceeding 32 mg/L was defined as high-level resistance to 
clarithromycin (Versalovic et al., 1997).
In our study, all of A2143G H. pylori mutants 
demonstrated low MIC values to clarithromycin (MICs 
≤32 mg/L), while in A2142G mutants we observed 
strains of both phenotypes; with high- or low-level of 
resistance. However, the results of our study showed 
that the strains with A2143G mutation had lower av-
erage MIC values than strains with A2142G mutation 
(6 mg/L and 30 mg/L, respectively). These results are 
consistent with those reported by other researchers who 
concluded that A2143G point mutation was correlated 
with lower clarithromycin MIC values than A2142G one 
(Stone et al., 1997; Versalovic et al., 1997; de Francesco et 
al., 2006; Gerrits et al., 2006; Raymond et al., 2007; Alva-
rez et al., 2009).
To conclude, PCR-RFLP method performed from 
pure H. pylori culture reduces the time of determina-
tion of clarithromycin resistance by about 4 days com-
paring to phenotypic methods of susceptibility testing. 
Faster detection of clarithromycin resistance enables 
selection of treatment regimen without clarithromycin 
according to EHSG recommendations, particularly in 
the regions of high clarithromycin resistance, such as 
Poland.
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